Antisoma announces positive ASA404 presentations at ASCO

[RandyW]

LONDON -- 05/30/08 -- Antisoma (LSE: ASM; USOTC:ATSMY) announces today details of two presentations on ASA404 that will be made at the upcoming 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO):

Abstract no. 8072 (poster) Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404); M. J. McKeage, M. B. Jameson, AS1404-201 Study Group Investigators; on Sunday 1 June, 2-6pm - Board 45c, in S Hall A1.

Abstract no. 5007 (oral presentation) Addition of DMXAA (ASA404) to docetaxel in patients with hormone-refractory metastatic prostate cancer (HRMPC): update from a randomized, phase II study; R. Pili, M. Rosenthal, AS1404-203 study group investigators; on Monday 2 June, 11.30-11.45am in Clinical Science Symposium on 'Novel antiangiogenic mechanisms' in Room W375a.

Enquiries:

Glyn Edwards, CEO

Daniel Elger, Director of Communications +44 (0)7909 915 068

Antisoma plc

Mark Court/Lisa Baderoon/Rebecca Skye +44 (0)20 7466 5000

Dietrich

Buchanan Communications

Brian Korb +1 646 378 2923

The Trout Group

[CaroleHammett]

Randy:

Re your above-noted Abstract 8072, the following is the abstract as published by ASCO:

http://www.asco.org/ASCO/Abstracts+%26+ ... ctID=31916

Abstracts > 2008 ASCO Annual Meeting

Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404).

Sub-category: Metastatic Lung Cancer

Category: Lung Cancer--Metastatic Lung Cancer

Meeting: 2008 ASCO Annual Meeting

Abstract No: 8072

Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 8072)

Author(s): M. J. McKeage, M. B. Jameson, AS1404-201 Study Group Investigators

Abstract:

Background: DMXAA (ASA404) is a tumor vascular disrupting agent recently evaluated in phase II trials in NSCLC. A randomized trial compared DMXAA 1,200 mg/m2 plus carboplatin and paclitaxel (CP) with CP alone (median survival 14.0 vs 8.8 months). A single-arm study evaluated DMXAA 1,800 mg/m2 plus CP (median survival 14.9 months). Both trials included squamous and non-squamous patients. We examined whether the safety or efficacy of DMXAA varied with histology.

Methods: Patients had chemotherapy-naïve stage IIIb/IV NSCLC. Phase II data were pooled by histology and treatment, with aggregation of the two DMXAA doses. We compared efficacy and safety between squamous and non-squamous patients receiving the same treatment. Then for each histology we compared patients receiving and not receiving DMXAA.

Results: Numbers of patients evaluable for safety (efficacy) were: in the CP arm of the randomized study, 11 (11) squamous and 25 (25) non-squamous; in the CP + DMXAA 1,200 mg/m2 arm of the randomized study, 11 (11) squamous and 26 (23) non-squamous; and in the CP + DMXAA 1,800mg/m2 single arm study, 11 (10) squamous and 20 (20) non-squamous. Pooling data from the two DMXAA dose groups should not introduce bias because they contain similar proportions of squamous patients.

Conclusions: Addition of DMXAA to CP was generally well tolerated in both squamous and non- squamous patients. There was no evidence that DMXAA induced hemoptysis in either group. In both squamous and non-squamous patients, efficacy findings including survival were consistently better with DMXAA plus CP than with CP alone. The forthcoming phase III trial will therefore include both squamous and non-squamous patients. Safety and Efficacy

Squamous Non-squamous All histologies

CP CP + DMXAA CP CP + DMXAA CP CP + DMXAA

% patients with >1 adverse event NCI-CTC grade >3/severe 72.7% (n=11) 68.2% (n=22) 64.0% (n=25) 60.9% (n=46) 66.7% (n=36) 63.2% (n=68)

Response rate* 14.3% (n=7) 40.0% (n=20) 25.0% (n=20) 31.7% (n=41) 22.2% (n=27) 34.4% (n=61)

Median time to tumor progression (months) 1.6 (n=11) 5.6 (n=21) 4.8 (n=25) 5.5 (n=43) 4.4 (n=36) 5.5 (n=64)

Median survival (months) 5.5 (n=11) 10.2 (n=21) 11.0 (n=25) 14.9 (n=43) 8.8 (n=36) 14.5 (n=64)

*12 patients evaluable for other efficacy parameters were not evaluable for response.

Associated Presentation(s):

1. Comparison of safety and efficacy between squamous and non-squamous non-small cell lung cancer (NSCLC) patients in phase II studies of DMXAA (ASA404).

No presentation available, please check back

Meeting: 2008 ASCO Annual Meeting

Presenter: Mark J McKeage

Session: Lung Cancer — Metastatic (General Poster Session)

© 2005-2008 American Society of Clinical Oncology (ASCO). All rights reserved worldwide.

----------

Thanks for bringing this to my attention, Randy!

Carole

Life is a Terminal Condition